Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas

Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas BRIEF REPORT Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas Giuseppe Giaccone, MD, PhD,*† Arun Rajan, MD,† Rita Ruijter, RN,* Egbert Smit, MD, PhD,‡ Cees van Groeningen, MD, PhD,* and Pancras C. W. Hogendoorn, MD, PhD§ tumor cells including those associated with Bcr-Abl, PDGFR, Abstract: Thymic malignancies are rare tumors of the mediastinum. and c-KIT. Striking activity has been observed with imatinib c-KIT is highly expressed in thymic carcinomas (TC) but infre- in chronic myelogenous leukemia and gastrointestinal quently in thymomas. Anecdotal experience suggests activity of 7,8 stroma cell tumors (GIST). imatinib mesylate in TC. Patients with unresectable World Health We performed this study to evaluate response of high- Organization B3 thymomas or TC, performance status 0 to 2, good grade thymic malignancies known to overexpress c-Kit to organ function, and measurable disease were enrolled in this study. imatinib mesylate. Imatinib was administered at 600 mg PO daily. Seven patients were recruited at one institution: two World Health Organization B3 PATIENTS AND METHODS thymomas and five TC. Imatinib treatment was generally well tolerated. Two patients had stable disease and five progressed. Patients Median survival was 4 months, and median time to progression was This was an http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas

Loading next page...
 
/lp/wolters-kluwer-health/imatinib-mesylate-in-patients-with-who-b3-thymomas-and-thymic-cms0RkLyEw

References (17)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181b6be57
pmid
20197733
Publisher site
See Article on Publisher Site

Abstract

BRIEF REPORT Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas Giuseppe Giaccone, MD, PhD,*† Arun Rajan, MD,† Rita Ruijter, RN,* Egbert Smit, MD, PhD,‡ Cees van Groeningen, MD, PhD,* and Pancras C. W. Hogendoorn, MD, PhD§ tumor cells including those associated with Bcr-Abl, PDGFR, Abstract: Thymic malignancies are rare tumors of the mediastinum. and c-KIT. Striking activity has been observed with imatinib c-KIT is highly expressed in thymic carcinomas (TC) but infre- in chronic myelogenous leukemia and gastrointestinal quently in thymomas. Anecdotal experience suggests activity of 7,8 stroma cell tumors (GIST). imatinib mesylate in TC. Patients with unresectable World Health We performed this study to evaluate response of high- Organization B3 thymomas or TC, performance status 0 to 2, good grade thymic malignancies known to overexpress c-Kit to organ function, and measurable disease were enrolled in this study. imatinib mesylate. Imatinib was administered at 600 mg PO daily. Seven patients were recruited at one institution: two World Health Organization B3 PATIENTS AND METHODS thymomas and five TC. Imatinib treatment was generally well tolerated. Two patients had stable disease and five progressed. Patients Median survival was 4 months, and median time to progression was This was an

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Oct 1, 2009

There are no references for this article.